BACKGROUND AND PURPOSE Early thrombolytic therapy with recombinant tissue-type plasminogen activator is a theoretically attractive approach to the treatment of acute focal cerebral ischemia. In preparation for a larger multicenter trial, three centers piloted a protocol for a randomized, double-blind, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator begun wi...

PURPOSE To report the use of intracameral tissue plasminogen activator to dissolve fibrinous membranes and break posterior synechiae in patients with acute HLA-B27-positive iridocyclitis with impending pupillary block. METHODS Two patients with severe acute fibrinous iridocyclitis and seclusio pupillae were identified. Because of the concern of impending pupillary block, intracameral tissue p...

We studied thrombolysis in an animal model of embolic stroke to determine the safety of tissue plasminogen activator and streptokinase. We occluded the middle cerebral arteries of 137 rabbits with radiolabeled blood clots and administered tissue plasminogen activator (n=49), streptokinase («=40), or saline (n=48) at various times after embolization. We assessed the rate of thrombolysis and cere...

In an attempt to investigate the effect of tissue plasminogen activator in the resolution of intracerebral haematoma an experimental model of intracerebral haematoma was designed in the cat. A total of 24 adult cats were studied. Intracerebral hematomas were provoked by stereotaxically injecting 0.2 ml of dotted human blood into the left frontal lobe. Control animals received 0.2 ml of normal s...

AIMS To identify the relative contribution of plasminogen activators, particularly tissue plasminogen activator (t-PA) and specific plasminogen activator inhibitors (PAI-1, PAI-2), to the fibrinolytic changes associated with various types of liver disease or severe chemical and physical damage to the liver. METHODS Platelet rich (PRP) and platelet poor plasma (PFP) from patients with alcoholi...

Tissue-type plasminogen activator (t-PA) is less active in vivo and in vitro against clots that are enriched in platelets, even at therapeutic concentrations. The release of radioactivity from ‘El-fibrin-labeled clots was decreased by 47% 6 hours after the addition of t-PA 400 U/mL when formed in plateletrich versus platelet-poor plasma. This difference was not due to the release of plasminogen...

The observation that aspirin inhibits the increment in tissue plasminogen activator ft-PA) activity induced by venous occlusion of the forearm became controversial with the publication of several nonconfirmatory studies. The current study was performed to confirm the original observation and determine the mechanism by which aspirin suppresses the incremental t-PA activity induced by venous occl...

The effect of thrombin on release of plasminogen activators (PAs) was studied using cultivated endothelial cells of the bovine cornea. Species of PAs released into the conditioned medium were determined by fibrin autography and immunological analyses. Chromogenic peptide (S-2251) microassay was used for a quantitative estimation of the PA activity in conditioned medium and enzyme-linked immunos...